+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Does growth hormone prevent aging in the healthy elderly with low serum insulin-like growth factor-I ?



Does growth hormone prevent aging in the healthy elderly with low serum insulin-like growth factor-I ?



Mechanisms of Ageing and Development 125(4): 291-295



Aging is associated with a gradual decline in the function of a number of endocrine glands. While there are phenotypic similarities seen in the changes of aging with some endocrine hormone deficiency states, the relationship between the decline in growth hormone (GH) secretion, and the decrease in serum insulin-like growth factor-I (IGF-I), with these body composition changes is far from clear. The decline in serum IGF-I, unlike that of thyroxine and estradiol, is not accompanied by an increase in pituitary GH secretion. The recent enthusiastic recommendation for GH 'replacement' in the aging population with low serum IGF-I remains highly controversial. The evidence is still unclear on any significant beneficial effect of such replacement in healthy fit elderly men and women. There is some early evidence of beneficial effects of such replacement in the frail elderly. There are no studies that have investigated the effect of GH on longevity in humans, but results from animal studies on caloric restriction and longevity do not suggest that GH administration will increase life span. There is still insufficient evidence that treatment with exogenous GH in the healthy elderly that attains serum IGF-I levels similar to that of young adults is beneficial or safe.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011973927

Download citation: RISBibTeXText

PMID: 15063105

DOI: 10.1016/j.mad.2004.01.005


Related references

Oral intake of selenium has no effect on the serum concentrations of growth hormone, insulin-like growth factor-1, insulin-like growth factor-binding proteins 1 and 3 in healthy women. European Journal of Clinical Chemistry and Clinical Biochemistry 33(7): 411-415, 1995

Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proceedings of the National Academy of Sciences of the United States of America 94(14): 7537-7542, 1997

Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 Levels in healthy elderly individuals. Relation to self-reported quality of health and disability. Gerontology 44(5): 277-280, 1998

Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Human Reproduction 12(10): 2123-2128, 1997

Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during menstrual cycle. Human Reproduction 12(10): 2123-2128, 1997

Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility 71(2): 261-267, 1999

Growth hormone, insulin-like growth factor-1 and growth hormone response to growth hormone releasing hormone in the elderly male are augmented considerably by donepezil, a drug for Alzheimers disease. European Urology Suppl.s 3(2): 63, 2004

Influence of gender on serum growth hormone, insulin-like growth factor-I and its binding protein-3 during aging. Yonsei Medical Journal 50(3): 407-413, 2009

Stimulation of the growth hormone -insulin-like growth factor I axis by daily oral administration of a GH secretogogue in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism 81(12): 4249-4257, 1996

Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism 81(12): 4249-4257, 1996

Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. Journal of Medical Case Reports 4: 305, 2010

Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young and middle-aged men. Clinical Endocrinology 44(6): 659-664, 1996